Late stent thrombosis after implantation of a sirolimus‐eluting stent

Kerner, Arthur; Gruberg, Luis; Kapeliovich, Michael; Grenadier, Ehud

doi:10.1002/ccd.10712

Cited by 52 publications

(19 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the criteria were broadened to include patients with PCI, stroke, PAD and STEMI, most of the retrieved data were for patients who had undergone PCI. Of these: five RCTs, 50-54 two observational cohorts, 38,55 nine case series, 56-64 and 33 case reports across 17 publications [65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81] investigated clopidogrel and ticlopidine therapy. Only two case series 82,83 and two case reports in a single publication 84 were identified for patients who had not undergone PCI.…”

Section: Quantity Of Research Availablementioning

confidence: 99%

The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis

Rogowski

Burch²,

Palmer³

et al. 2009

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in t...

show abstract

Section: Quantity Of Research Availablementioning

confidence: 99%

The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis

Rogowski

Burch²,

Palmer³

et al. 2009

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Although subacute thrombosis has received great attention related to drug-eluting stents, it must be remembered that it also occurred with bare metal stents [64,65,66,67,68,69,70,71]. Registry studies documented an incidence of 0.6–0.9% of patients with bare metal stents [64].…”

Section: Drug-eluting Stentsmentioning

confidence: 99%

Antiplatelet Therapy after Percutaneous Coronary Intervention

Holmes¹

2006

Cerebrovasc Dis

View full text Add to dashboard Cite

There is intense interest in the relationship between inflammation, thrombosis, platelet aggregation, and hyperlipidemia in patients with coronary artery disease. The specific role of inflammation with its linkage to the coagulation cascade has been well studied. A number of inflammatory markers have been identified which can be used for risk stratification in patients with acute coronary syndromes. Patients with acute coronary syndromes at the time of presentation often have an underlying inflammatory state which needs therapy with antiplatelet regimens including now increasingly frequently clopidogrel in addition to the standard of aspirin. In those patients who are treated medically for their acute coronary syndromes, long-term treatment with dual antiplatelet therapy has been documented to be associated with improved outcome. In patients who undergo an invasive approach with placement of intracoronary stents, the importance of dual antiplatelet therapy is increased. Drug-eluting stents are now used in approximately 90% of all interventional procedures. There is evidence to suggest that while these patients have improved outcome in terms of a decreased need for subsequent procedures to treat restenosis, there is the potential for late subacute stent thrombosis. When late subacute stent thrombosis occurs, it results in mortality or infarction in 40–60% of patients. Dual antiplatelet therapy is therefore recommended for an increasingly longer time in this patient group. At the present time, protocols indicate 3 months for one of the drug-eluting stents and 6 months for the other. However, increasingly longer antiplatelet therapy is being used clinically. Assessment of platelet function during follow-up is as yet early. There are issues about which specific test to use and the definition of platelet hyperreactivity. In the future, more individually targeted therapy may be possible if we can more adequately assess the degree of hyperreactivity and underlying inflammation.

show abstract

“…3 Stent thrombosis usually results in ST-segment elevation myocardial infarction (MI) or death, 4 and in the era of DESs, late stent thrombosis may be a possible limitation of the procedure. In the international reports of late angiographic stent thrombosis (LAST), [5][6][7][8][9][10] clopidogrel was used as the antiplatelet therapy in most patients/studies. As antithrombotic therapies have a major impact on angiographic stent thrombosis after BMS or DES implantation, 11,12 we wanted to evaluate the incidence, promoting factors and outcomes of LAST in Japan where clopidogrel has not been approved.…”

mentioning

confidence: 99%

Late Angiographic Stent Thrombosis After Sirolimus-Eluting Stent Implantation

Takahashi

Kaneda

Tanaka

et al. 2007

Circ J

View full text Add to dashboard Cite

Background Although drug-eluting stents dramatically reduce revascularization after percutaneous coronary intervention (PCI), it is still unclear whether they increase the risk of stent thrombosis. Late stent thrombosis (>30 days) was a very rare complication after bare metal stent implantation. Four cases of confirmed late angiographic stent thrombosis (LAST) after sirolimus-eluting stent (SES) implantation are presented and the incidence, promoting factors and outcomes of such cases in Japan, where clopidogrel has not been approved, are described. Methods and ResultsBetween September 2004 and March 2006, 725 patients underwent PCI with SES implantation and 679 patients (94%) were clinically followed up (median 271 days). There were 4 cases (0.6%) of LAST (at 60, 180, 215, and 508 days, respectively) after elective SES implantation resulting in myocardial infarction. Three cases occurred soon after antiplatelet therapy discontinuation 3 patients died after LAST events. The incidence of LAST was 0.6%. Conclusions LAST is a rare complication, even after SES implantation, at least in patients with appropriate antiplatelet therapy. However, as it can lead to fatal complications, it must be taken into account, especially when antiplatelet therapy is discontinued. (Circ J 2007; 71: 226 -228)

show abstract

Late stent thrombosis after implantation of a sirolimus‐eluting stent

Cited by 52 publications

References 10 publications

The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis

The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis

Antiplatelet Therapy after Percutaneous Coronary Intervention

Late Angiographic Stent Thrombosis After Sirolimus-Eluting Stent Implantation

Contact Info

Product

Resources

About